Latest News for: braf

Edit

Royal Hospital achieves breakthrough with colorectal cancer diagnostic testing

Muskat Daily 20 Jan 2026
This development, led by the Department of Medical Laboratories and the Histology and Cytology Section, marks the first time that specific genetic tests—KRAS, NRAS, and BRAF—have been performed within the Sultanate of Oman ... ....
Edit

Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea (ONO Pharmaceutical Co Ltd)

Public Technologies 13 Jan 2026
As no drugs have been approved for the first-line treatment of BRAF-mutant CRC, there is a high unmet need for this cancer and Braftovi will be a new treatment option ... Braftovi is a small molecule BRAF kinase inhibitor.
Edit

Understanding the BRAF and mTOR Pathway

Rumble 09 Dec 2025
Click the Rumble article link to see the video ....
Edit

New drug combo nearly doubles survival for BRAF-mutated lung cancer patients, trial shows

The Jerusalem Post 27 Nov 2025
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress ....
Edit

Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer (ONO Pharmaceutical Co Ltd)

Public Technologies 20 Nov 2025
encorafenib) Capsule (“Braftovi”), a BRAF inhibitor, in combination with cetuximab, an anti-human EGFR monoclonal antibody, and chemotherapy for the indication of unresectable, advanced or recurrent colorectal cancer (CRC) with BRAF mutation.
Edit

SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines (Bicara Therapeutics Inc)

Public Technologies 08 Nov 2025
) Dual targeting of TGF-β and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines ... BRAF-V600.
Edit

RP1 + Nivolumab in Patients with and without prior BRAF-Directed Therapy at SITC 2025 (Replimune Group Inc)

Public Technologies 07 Nov 2025
Overall, 86.5% (77/89) and 94.1% (48/51) of patients with BRAF-WT and BRAF-mut melanoma, respectively, experienced at least 1 treatment-related adverse event (TRAE) of any grade (Table 3).
Edit

BRAF inhibition increases TGFβ2 production and stimulates metastasis in mice with endogenous BRAFV600E-induced hepatocellular carcinoma

PNAS 06 Nov 2025
.
  • 1

Article Search

tools
×
×
×
×